These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 15256768)

  • 1. Chenodeoxycholic acid (CDCA) treatment during pregnancy in women with cerebrotendinous xanthomatosis (CTX): Lessons learned from 19 pregnancies.
    Zaccai TCF; Hassin-Baer S; Kfir NC; Duell PB; Neerhof M; Sloma R; Roitman M; Kisanuki YY; Verrips A; DeBarber AE
    Genet Med; 2024 May; 26(5):101086. PubMed ID: 38288684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cerebrotendinous xanthomatosis in pregnancy: Patient and physician perspectives.
    Duell PB; Dutta R; Wolf A; Rosengrant H
    J Clin Lipidol; 2023; 17(5):700-703. PubMed ID: 37543441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Postprandial Bile Acid Profiles and Glucose Metabolism in Cerebrotendinous Xanthomatosis.
    Majait S; Meessen ECE; Vaz FM; Kemper EM; Nierop SV; Olde Damink SW; Schaap FG; Romijn JA; Nieuwdorp M; Verrips A; Knop FK; Soeters MR
    Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Product development and quality of pharmacy compounded chenodeoxycholic acid capsules for Dutch cerebrotendinous xanthomatosis patients.
    Bouwhuis N; Jacobs BAW; Kemper EM
    Front Pharmacol; 2023; 14():1264997. PubMed ID: 37915417
    [No Abstract]   [Full Text] [Related]  

  • 5. Endoscopic resection of tendon xanthoma in the elbow of a patient with cerebrotendinous xanthomatosis.
    Nakazawa K; Yano K; Kaneshiro Y; Sakanaka H
    BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34772677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Living with Cerebrotendinous Xanthomatosis: Patient, Caregiver, and Expert Perspectives.
    Steiner RD; DeBarber A; Larson A; Blanchard B; Laurie S; Odedara N; Rosengrant H; Dutta R
    Adv Ther; 2024 Feb; 41(2):467-475. PubMed ID: 38110654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chenodeoxycholic Acid Improves Embryo Implantation and Metabolic Health through Modulating Gut Microbiota-Host Metabolites Interaction during Early Pregnancy.
    Chen M; Zhao Y; Ji H; Li L; Liu H; Wang S; Zhang D; Yin J; Wang J; Zhang X
    Antioxidants (Basel); 2023 Dec; 13(1):. PubMed ID: 38275628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology and Treatment of Lipid Abnormalities in Cerebrotendinous Xanthomatosis: An Integrative Review.
    Ribeiro RM; Vasconcelos SC; Lima PLGSB; Coelho EF; Oliveira AMN; Gomes EABM; Mota LA; Radtke LS; Carvalho MDS; Araújo DABS; Pinheiro MSN; Gama VCV; Júnior RMM; Braga Neto P; Nóbrega PR
    Brain Sci; 2023 Jun; 13(7):. PubMed ID: 37508912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice.
    Gautier T; de Haan W; Grober J; Ye D; Bahr MJ; Claudel T; Nijstad N; Van Berkel TJC; Havekes LM; Manns MP; Willems SM; Hogendoorn PCW; Lagrost L; Kuipers F; Van Eck M; Rensen PCN; Tietge UJF
    J Lipid Res; 2013 Aug; 54(8):2195-2205. PubMed ID: 23620138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.
    Verrips A; Wevers RA; Van Engelen BG; Keyser A; Wolthers BG; Barkhof F; Stalenhoef A; De Graaf R; Janssen-Zijlstra F; Van Spreeken A; Gabreëls FJ
    Metabolism; 1999 Feb; 48(2):233-8. PubMed ID: 10024088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease.
    Keren Z; Falik-Zaccai TC
    Pediatr Endocrinol Rev; 2009 Sep; 7(1):6-11. PubMed ID: 19696711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
    Salen G; Steiner RD
    J Inherit Metab Dis; 2017 Nov; 40(6):771-781. PubMed ID: 28980151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced susceptibility of LDL to oxidative modification in a CTX patient:- role of chenodeoxycholic acid in xanthoma formation.
    Kinoshita M; Kawamura M; Fujita M; Hirota D; Suda T; Taki M; Kusano J; Takao K; Takenaka H; Kubota S; Teramoto T
    J Atheroscler Thromb; 2004; 11(3):167-72. PubMed ID: 15256768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
    Huidekoper HH; Vaz FM; Verrips A; Bosch AM
    Eur J Pediatr; 2016 Jan; 175(1):143-6. PubMed ID: 26156051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.
    Verrips A; Dotti MT; Mignarri A; Stelten BML; Verma S; Federico A
    Neurol Sci; 2020 Apr; 41(4):943-949. PubMed ID: 31863326
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.